Clinical validation of a point-of-care antibody test for COVID-19
Patel, M.; Lakhotia, Y.; Shah, S.; Suthar, N.; Kola, S.; Rangarajan, R.
Show abstract
The objective of this study was to evaluate the performance of a lateral flow antibody test for COVID-19, approved for use in India. Although many point-of-care antibody tests are available globally, they have been subjected to limited clinical validation. This has led to suboptimal outcomes in the field, where antibody tests play a significant role in tracking the immunity of individuals and communities. In this study an antibody test, ImmunoQuick that recognizes antibodies to the Nucleocapsid and Spike proteins of SARS CoV-2 was tested in 100 symptomatic patients with a positive or negative diagnosis of COVID-19, based on RT-PCR results. The overall sensitivity of the test was found to be 86.1% (95% CI: 76.4% to 92.8%) and specificity 100% (95% confidence interval: 73.5% to 100%). The sensitivity reached a peak of 95.7% with samples taken 17 days after the onset of symptoms. Overall, the sensitivity and specificity of the test are sufficient for assessing seroprevalence.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Development And Performance Evaluation of A Rapid In-House ELISA for Retrospective Serosurveillance of SARS-CoV-2 96%
- Development and Evaluation of Two Rapid Indigenous IgG-ELISA immobilized with ACE-2 Binding Peptides for Detection Neutralizing Antibodies Against SARS-CoV-2 96%
- Evaluation of SARS-CoV-2 Antibody Point of Care Devices in the Laboratory and Clinical Setting 96%
Similar papers in this journal
Similar papers in this journal
- Age significantly influences the sensitivity of SARS-CoV-2 rapid antibody assays 97%
- Performance of SARS-CoV-2 rapid antigen test compared with real-time RT-PCR in asymptomatic individuals 96%
- Performance evaluation of novel fluorescent-based lateral immune flow assay (LIFA) for rapid detection and quantitation of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individuals 95%
Similar papers in this journal
- Are commercial antibody assays substantially underestimating SARS-CoV-2 ever infection? An analysis on a population-based sample in a high exposure setting 96%
- Kinetics and seroprevalence of SARS-CoV-2 antibodies – a comparison of 3 different assays 95%
- Standard blood laboratory results in SARS-CoV-19 positive patients: do they show a typical pattern? 94%
Similar papers in this journal
- Performance of a point of care test for detecting IgM and IgG antibodies against SARS-CoV-2 and seroprevalence in blood donors and health care workers in Panama 96%
- Clinical significance of IgM and IgG test for diagnosis of highly suspected COVID-19 infection 94%
- SARS-CoV-2 testing in the Slovak Republic from March 2020 to September 2022 – summary of the pandemic trends 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.